Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 8/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21396350 | 0.91 | PNP (0.41) | DHFRPNPXDHHPRT1TLR7 | |
| SCHEMBL21396371 | 0.85 | CYP3A4 (0.36) | CYP3A4MAPTPNPXDHTYMS | |
| SCHEMBL21396346 | 0.84 | PNP (0.43) | DHFRPNPHPRT1 | |
| SCHEMBL21396412 | 0.82 | PNP (0.36) | PNPHPRT1TLR7 | |
| SCHEMBL21396490 | 0.78 | CYP3A4 (0.42) | DHFRCYP3A4MAPTPNPHPRT1 | |
| SCHEMBL21396508 | 0.78 | PNP (0.36) | DHFRCYP3A4MAPTPNPHPRT1 | |
| SCHEMBL21396502 | 0.77 | PNP (0.37) | CYP3A4MAPTPNPHPRT1TLR7 | |
| SCHEMBL21396411 | 0.74 | RXFP1 (0.40) | MAPT | |
| SCHEMBL21396531 | 0.73 | PNP (0.33) | CYP3A4MAPTPNPHPRT1TLR7 | |
| SCHEMBL23921002 | 0.72 | PNP (0.50) | DHFRCYP3A4MAPTPNPXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PDE7A, PRKG1, PDE4C | DHFR 2846/4885CYP3A4 4066/4885MAPT 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.